» Articles » PMID: 35955962

Ketogenic and Low FODMAP Diet in Therapeutic Management of a Young Autistic Patient with Epilepsy and Dysmetabolism Poorly Responsive to Therapies: Clinical Response and Effects of Intestinal Microbiota

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Aug 12
PMID 35955962
Authors
Affiliations
Soon will be listed here.
Abstract

Autism spectrum disorder (ASD) is often associated with several intestinal and/or metabolic disorders as well as neurological manifestations such as epilepsy (ASD-E). Those presenting these neuropathological conditions share common aspects in terms of gut microbiota composition. The use of microbiota intervention strategies may be an approach to consider in the management of these cases. We describe the case of a 17-year-old girl affected by ASD, reduced growth, neurological development delay, mutations in the PGM1 and EEF1A2 genes (in the absence of clinically manifested disease) and, intestinal disorders such as abdominal pain and diarrhea associated with weight loss. As she demonstrated poor responsiveness to the therapies provided, we attempted two specific dietary patterns: a ketogenic diet, followed by a low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet, with the aim of improving her neurological, metabolic, and intestinal symptoms through modulation of the gut microbiota's composition. The ketogenic diet (KD) provided a reduction in , , and . Although her intestinal symptoms improved, KD was poorly tolerated. On the other hand, the passage to a low FODMAPs diet produced a significant improvement in all neurological, intestinal, and metabolic symptoms and was well-tolerated. The following gut microbiota analysis showed reductions in Actinobacteria, , , and . The alpha biodiversity was consistently increased and the / ratio decreased, reducing the extent of fermentative dysbiosis. Gut microbiota could be a therapeutic target to improve ASD-related symptoms. Further studies are needed to better understand the correlation between gut microbiota composition and ASD, and its possible involvement in the physiopathology of ASD.

Citing Articles

Ketogenic diet as a therapeutic approach in autism spectrum disorder: a narrative review.

Ozturk E, Aslan Cin N, Cansu A, Akyol A Metab Brain Dis. 2024; 40(1):67.

PMID: 39692905 DOI: 10.1007/s11011-024-01506-5.


Wine, Polyphenols, and the Matrix Effect: Is Alcohol Always the Same?.

Miraldi E, Baini G, Biagi M, Cappellucci G, Giordano A, Vaccaro F Int J Mol Sci. 2024; 25(18).

PMID: 39337284 PMC: 11432751. DOI: 10.3390/ijms25189796.


A long journey to treat epilepsy with the gut microbiota.

Li Q, Gu Y, Liang J, Yang Z, Qin J Front Cell Neurosci. 2024; 18:1386205.

PMID: 38988662 PMC: 11233807. DOI: 10.3389/fncel.2024.1386205.


The interplay between microbiota and brain-gut axis in epilepsy treatment.

Zhu H, Wang W, Li Y Front Pharmacol. 2024; 15:1276551.

PMID: 38344171 PMC: 10853364. DOI: 10.3389/fphar.2024.1276551.


Bioinformatics analysis of the diversity of gut microbiota and different microbiota on insulin resistance in diabetes mellitus patients.

Guo Q Heliyon. 2023; 9(12):e22117.

PMID: 38125495 PMC: 10730988. DOI: 10.1016/j.heliyon.2023.e22117.


References
1.
Tagg J, Dierksen K . Bacterial replacement therapy: adapting 'germ warfare' to infection prevention. Trends Biotechnol. 2003; 21(5):217-23. DOI: 10.1016/S0167-7799(03)00085-4. View

2.
Nogay N, Walton J, Roberts K, Nahikian-Nelms M, Witwer A . The Effect of the Low FODMAP Diet on Gastrointestinal Symptoms, Behavioral Problems and Nutrient Intake in Children with Autism Spectrum Disorder: A Randomized Controlled Pilot Trial. J Autism Dev Disord. 2020; 51(8):2800-2811. DOI: 10.1007/s10803-020-04717-8. View

3.
Tagliabue A, Ferraris C, Uggeri F, Trentani C, Bertoli S, De Giorgis V . Short-term impact of a classical ketogenic diet on gut microbiota in GLUT1 Deficiency Syndrome: A 3-month prospective observational study. Clin Nutr ESPEN. 2017; 17:33-37. DOI: 10.1016/j.clnesp.2016.11.003. View

4.
Catinean A, Neag A, Nita A, Buzea M, Buzoianu A . Spores-A Promising Treatment Option for Patients with Irritable Bowel Syndrome. Nutrients. 2019; 11(9). PMC: 6770835. DOI: 10.3390/nu11091968. View

5.
Mancabelli L, Milani C, Lugli G, Turroni F, Mangifesta M, Viappiani A . Unveiling the gut microbiota composition and functionality associated with constipation through metagenomic analyses. Sci Rep. 2017; 7(1):9879. PMC: 5575163. DOI: 10.1038/s41598-017-10663-w. View